Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13093691 | 0.92 | OPRM1 (0.41) | OPRM1MEN1MAPTKMT2A | |
| SCHEMBL14049046 | 0.91 | IKBKB (0.45) | OPRM1MEN1POLBMAPTKMT2A | |
| SCHEMBL14049089 | 0.87 | OPRD1 (0.36) | OPRM1MEN1POLBKMT2A | |
| SCHEMBL2878751 | 0.85 | NR1I2 (0.39) | MEN1POLBMAPTCRHBPKMT2A | |
| SCHEMBL13093703 | 0.85 | MEN1 (0.36) | OPRM1MEN1POLBMAPTCRHBP | |
| SCHEMBL14136645 | 0.85 | PTPN1 (0.41) | OPRM1MEN1POLBMAPTKMT2A | |
| SCHEMBL14136642 | 0.84 | KDM4E (0.42) | OPRM1MEN1MAPTKMT2A | |
| SCHEMBL14048975 | 0.84 | KDM4E (0.42) | OPRM1MEN1MAPTKMT2A | |
| SCHEMBL14049055 | 0.84 | ALDH1A1 (0.44) | OPRM1MEN1POLBMAPTKMT2A | |
| SCHEMBL14049057 | 0.83 | KDM4E (0.44) | OPRM1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-10-30 | — | — | US | disclosed |
| US-7402608-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2008-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269481-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | ZC3HAV1, ZYX, ZFX | OPRM1 4348/4885MEN1 3705/4885POLB 3431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.